Evaluation of Pregnancy Associated Plasma Protein A (PAPPA) as a Biomarker in Breast Cancer.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06174571

Enrollment

Registered

2023-12-18

Start date

2024-02-01

Completion date

2026-03-01

Last updated

2023-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This work aims to: 1. Evaluation of the role of pregnancy associated plasma protein A( PAPPA ) in diagnosis & early detection of breast cancer. 2. Evaluation of the relationship between ( PAPPA ) levels and stages of breast cancer.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Inclusion criteria

* female patients with breast cancer who were diagnosed by histopathological studies and did not receive any treatment.

Exclusion criteria

* Patients who received chemotherapy or radiotherapy. * Patients with known other organ malignancy.

Design outcomes

Primary

Measure	Time frame	Description
Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer.	baseline	Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer.

Contacts

Primary ContactAya Hasan Abdulhady

ayahhasan99@gmail.com01146471617

Outcome results